Skip to main content

Vyant Bio, Inc.

VYNTDelisted May 4, 2023
Industry
Services-Medical Laboratories
SEC CIK
0001349929

Vyant Bio, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 17 institutions reported holding it in 13F filings for Q1 2023, worth $136.8K in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Vyant Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Vyant Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Vyant Bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hansen Paul R.Director159,778Feb 27, 20230
Fletcher R JohnDirector23,895Jan 19, 20230
Horobin JoannaDirector23,123Jan 19, 20230
Harris Geoffrey E.Director19,761Jan 19, 20230
Boehm MarcusDirector56,484Apr 19, 20220
McLeod HowardDirector43,927Apr 1, 20220
Yeh Yung-PingDirector56,240Apr 1, 20220
Roberts John AChief Executive Officer39,807Mar 17, 20220
LaFrence Andrew D.C.Chief Financial Officer34,292Mar 17, 20220
Fremeau Robert Thomas Jr.Chief Scientific Officer1,000Mar 17, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 22, 2022 (view filing)Nov 184 daysHarris Geoffrey E.DirectorSSaleCommon Stock, $0.0001 par value−765$1.33−$1.02K−5.2%14.0K after2 lots
Dec 29, 2021 (view filing)Nov 2336 daysLaFrence Andrew D.C.Chief Financial OfficerPPurchaseCommon Stock, $0.0001 par value+5.00K$2.00+$10.0K+17.1%34.3K afterAmended
Dec 7, 2021 (view filing)Dec 61 dayBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+5.00K$1.69+$8.45K+4.0%128.8K after
Nov 24, 2021 (view filing)Nov 24Same dayRoberts John AChief Executive OfficerPPurchaseCommon Stock, $0.0001 par value+5.00K$2.02+$10.1K+14.4%39.8K after
Nov 23, 2021 (view filing)Nov 221 dayYeh Yung-PingChief Innovation OfficerPPurchaseCommon Stock, $0.0001 par value+500$2.05+$1.02K+4.1%12.8K after
Nov 17, 2021 (view filing)Oct 2820 daysLateFremeau Robert Thomas Jr.Chief Scientific OfficerPPurchaseCommon Stock, $0.0001 par value+1.00K$2.19+$2.19KNew position1.00K after
Oct 28, 2021 (view filing)Oct 271 dayBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+5.00K$2.10+$10.5K+4.2%123.8K after
Sep 30, 2021 (view filing)Sep 291 dayBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+5.00K$2.44+$12.2K+4.4%118.8K after
Aug 27, 2021 (view filing)Aug 252 daysYeh Yung-PingChief Innovation OfficerPPurchaseCommon Stock, $0.0001 par value+1.00K$2.64+$2.64K+8.9%12.3K after
Aug 26, 2021 (view filing)Aug 251 dayBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+5.00K$2.58+$12.9K+4.6%113.8K after
Aug 25, 2021 (view filing)Aug 232 daysRoberts John AChief Executive OfficerPPurchaseCommon Stock, $0.0001 par value+10.4K$2.41+$25.1K+42.6%34.8K after
Aug 23, 2021 (view filing)Aug 194 daysHansen Paul R.DirectorPPurchaseCommon Stock, $0.0001 par value+20.0K$2.35+$47.0K+3.3%618.0K after
Jul 28, 2021 (view filing)Jul 28Same dayBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+5.00K$2.92+$14.6K+4.8%108.8K after
Jul 1, 2021 (view filing)May 28-Jun 3034 daysBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+10.0K$3.72+$37.2K+10.7%103.8K afterAmended2 lots
Jul 1, 2021 (view filing)Jun 301 dayBoehm MarcusDirectorPPurchaseCommon Stock, $0.0001 par value+5.00K$3.76+$18.8K+5.1%103.9K after